Azaindole therapeutic agents.

Azaindole therapeutic agents.
复制标题

DOI:
10.1016/j.bmc.2020.115830
复制
发表时间:
2020-12-15
影响因子:
3.5
通讯作者:
Ganesh T
Ganesh T
中科院分区:
医学3区
文献类型:
--
作者:
Motati DR;Amaradhi R;Ganesh T

文献摘要

参考文献

被引文献

相似文献

氮杂吲哚结构框架是多种具有生物活性的天然和合成有机分子以及多种经美国食品药品监督管理局(FDA)批准用于治疗各种疾病的药物的组成部分。在过去十年中,出现了大量文献报道,描述了多种氮杂吲哚分子的药理学、生物活性和治疗应用。这促使有机化学和药物化学领域开发各种氮杂吲哚的新型合成方法,并针对多种生物靶点测试其生物活性。在此,我们总结了具有治疗优势的临床候选药物以及几种包含氮杂吲哚结构部分的临床前候选药物的生物活性。
Azaindole structural framework is an integral part of several biologically active natural and synthetic organic molecules; and several FDA approved drugs for various diseases. In the last decade, quite a number of literature reports appeared describing the pharmacology, biological activity and therapeutic applications of a variety of azaindole molecules. This prompted the organic and medicinal chemistry community to develop novel synthetic methods for various azaindoles and test them for a bioactivity against a variety of biological targets. Herein, we have summarized the biological activity of therapeutically advanced clinical candidates and several preclinical candidate drugs that contain azaindole structural moiety.
DOI: 10.1021/jm4019178
发表时间: 2014-02-27
影响因子: 7.3
作者:
Harcken, Christian;Riether, Doris;Thomson, David S.
通讯作者: Thomson, David S.
DOI: 10.1021/jm401094t
发表时间: 2013-10-24
影响因子: 7.3
作者:
Goodfellow VS;Loweth CJ;Ravula SB;Wiemann T;Nguyen T;Xu Y;Todd DE;Sheppard D;Pollack S;Polesskaya O;Marker DF;Dewhurst S;Gelbard HA
通讯作者: Gelbard HA
DOI: 10.1021/acs.jmedchem.8b01187
发表时间: 2018-11-22
影响因子: 7.3
作者:
Foote, Kevin M.;Nissink, J. Willem M.;Jewsbury, Philip J.
通讯作者: Jewsbury, Philip J.
DOI: 10.1016/j.bmc.2013.12.031
发表时间: 2014-02-01
影响因子: 3.5
作者:
Cincinelli, Raffaella;Musso, Loana;Dallavalle, Sabrina
通讯作者: Dallavalle, Sabrina
DOI: 10.1021/acsmedchemlett.6b00487
发表时间: 2017-02-01
影响因子: 4.2
作者:
Bandarage, Upul K.;Clarke, Michael P.;Charifson, Paul S.
通讯作者: Charifson, Paul S.